Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic analysis of LN229 cell treated by unit of bortezomib and panobinostat

ABSTRACT: We report the application of unit of bortezomib and panobinostat on LN229 cell , and further explored the mechanism of drugs on GBM cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE206984 | GEO | 2022/06/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptomic analysis of LN229 cell treated by unit of bortezomib and panobinostat

Project description:Transcriptomic analysis of LN229 cell treated by unit of bortezomib and panobinostat

| PRJNA853204 | ENA

Effect of panobinostat, givinostat and ruxolitinib treatment in the anti-GBM mouse model of crescentic glomerulonephritis.

Project description:We demonstrated that in anti-glomerular basement membrane (anti-GBM) glomerulonephritis, crescents derived from clonal amplification of an immature subset of parietal epithelial cells (PECs) and that following treatment of mice with 3 different drugs currently used in haematological stem cell disorders (panobinostat, givinostat and ruxolitinib), only panobinostat exerted beneficial effect. To establish the mechanism of action of panobinostat, we generated single-cell RNA sequencing (scRNAseq) datasets of kidney cells obtained from control mice with anti-GBM glomerulonephritis and of mice treated with the three drugs. The analysis demonstrated that the drugs exerted similar effects on clusters of cells of the immune system, suggesting that all the three drugs elicit similar anti-inflammatory and immunosuppressive properties.

2022-09-24 | GSE195784 | GEO

Expression data of LN229 cells treated with 23 Pa compressive solid stress (CSS) or no CSS

Project description:Glioblastoma ( GBM) is an astrocytic brain tumor with median survival times of < 15 months, primarily as a result of high infiltrative potential and development of resistance to therapy (i.e., surgical resection, chemoradiotherapy). A prominent feature of the GBM microenvironment is compressive solid stress (CSS) caused by uninhibited tumor growth within the confined skull. We used microarrays to explore the gene expression of LN229 cells treated with 23 Pa CSS as compared to no CSS. The purpose is to detect the up-regulated genes induced by CSS.

2019-12-31 | GSE137210 | GEO

The effects on the deficient of GDH1 on gene expression in LN229 cells.

Project description:Glutamine is an important nutriment for cancer cell growth that provides biological sources for nucleic acid and fatty acid synthesis, but the role of glutaminolysis in signal transduction and glioblastoma (GBM) progression remains little known. Here, we investigated whether GDH1, a key glutamate dehydrogenase, affects the expression levels of signal transduction factors by mRNA expression profiling of wild-type and GDH1 knockdown cells of the glioblastoma cell line LN229 cells

2024-06-30 | GSE268158 | GEO

RNA-seq analysis of gene expression profile in PTEN WT and KO LN229 glioblastoma multiforme (GBM) Xenograft tumor Transcriptomes

Project description:The goal of this study is to compare gene expression profiles of PTEN WT and KO GBM cells when they are growing in vivo. Isogenic PTEN WT or KO LN229 GBM cells were subcutaneously implanted into Balb/c nude mice (two in each group) to form tumor. At the 30th day tumors were harvested and total RNA was isolated. RNA-seq analysis was performed to examine the differential express pattern of the two type of xenografts.

2019-09-04 | GSE136738 | GEO

Differential gene expression in neuroblastoma cells after treatment with vehicle control, JQ1, panobinostat, or combination of JQ1 and panobinostat

Project description:The bromodomain inhibitor JQ1 and the histone deacetylase inhibitor panobinostat induce synergistic anticancer effects We analyzed whether JQ1 and panobinostat synergistically modulate gene expression Neuroblastoma SK-N-BE(2) cells were treated with vehicle control, 1 microM JQ1, 10 nM panobinostat, or combination of JQ1 and panobinostat for 6 hours, and subjected to differential gene expression studies with Affymetrix microarrays.

2015-12-31 | E-GEOD-68690 | biostudies-arrayexpress

Plasma Mouse LC-MSMS - Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival

Project description:Patients diagnosed with glioblastoma (GBM) with sustained synthesis of the DNA repair enzyme, O6-methyl guanine DNA methytransferase (MGMT), are rendered resistant to Temozolomide (TMZ) chemotherapy. Here, we hypothesized that pretreatment with the proteasome inhibitor Bortezomib (BTZ, Velcade) might sensitize these GBM to TMZ by depleting MGMT.

2019-08-20 | PXD007193 | Pride

Targeting S6K1 and S6K2 by siRNA and sgRNA in LN229 GBM cells

Project description:Targeting S6K1 and S6K2 by siRNA and sgRNA in LN229 GBM cells

| PRJNA805545 | ENA

A Subset of Genes Can Distinguish between Bortezomib Responsive Versus Bortezomib Resistant Myeloma

Project description:Gene expression profile (GEP) was analyzed from cultured bone marrow (BM) samples from patients with bortezomib responsive versus bortezomib resistant myeloma after 6-8 hours incubation in vitro with bortezomib 2 µg/ml or with PBS. Case D also had a fresh BM sample taken 75 minutes after IV injection of bortezomib.

2013-11-01 | GSE51940 | GEO

NCI-H1688 cells treated with natural compounds(sanguinarine chloride, cepharanthine and evodiamine), or (+)-JQ-1, or panobinostat, or sanguinarine chloride in combination with panobinostat or (+)-JQ-1.

Project description:Purpose: we used next generation sequencing to analyze gene expression profiles of NCI-H1688 treated with different drugs and elaborated the combinatorial effect of sanguinarine chloride and panobinostat or (+)-JQ-1.The goals of this study are to compare the drug effect and find out the resonally synergistic effects in NCI-H1688.

2021-08-31 | GSE182821 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data